DETAILS

Property Name	Property Value	Unit	Raw Value	Raw Unit	Reference
Log P	0.8	-	0.8	-	DRUGBANK
Melting Point	48.5	℃	48-49	℃	Arnold, H., Brock, N. and Bourseaux, F.; U S . Patent 3,018,302; January 23,1962; assigned to Asta-Werke A.G. Chemische Fabrik (W. Germany).
Water Solubility	30000.0	mg/L	1-5	g/100ml	DRUGBANK

Property Name	Property Value	Unit	Raw Value	Raw Unit	Annotation	Factor	Reference
Bioavailability	74.0	%	74±22	%	PO, oral;		The Pharmacological Basis of Therapeutics
C Max	31591406.0	ng/ml	121±21	mM	intravenous injection, IV; breast cancer;		The Pharmacological Basis of Therapeutics
T Max	1.0	h	1	h	PO, oral;		DRUGBANK
Clearance	63.0	L/kg	63±7.6	L/kg	Total clearance;		DRUGBANK
Clearance	0.0780	L/h/kg	1.3±0.5	ml/min/kg		Children ↑ ;Hepatic cirrhosis, cirr ↓ ;RD, renal impairment, Renal disease，including uremia → ;	The Pharmacological Basis of Therapeutics
Clearance	0.0660	L/h/kg	1.1	ml/min/kg	intravenous injection, IV; human, homo sapiens;		Human Intravenous Pharmacokinetic Dataset
Volume of Distribution	40.0	L	30-50	L			DRUGBANK
Volume of Distribution	0.78	L/kg	0.78±0.57	L/kg		Children → ;	The Pharmacological Basis of Therapeutics
Volume of Distribution	0.73	L/kg	0.73	L/kg	intravenous injection, IV; human, homo sapiens;		Human Intravenous Pharmacokinetic Dataset
Half-life	7.5	h	3-12	h			DRUGBANK
Half-life	7.5	h	7.5±4.0	h		Children ↓ ;Hepatic cirrhosis, cirr ↑ ;	The Pharmacological Basis of Therapeutics
Half-life	8.0	h	8	h	intravenous injection, IV; human, homo sapiens;		Human Intravenous Pharmacokinetic Dataset
Eliminate Route	15.0	%	10-20	%	Urinary excretion; intravenous injection, IV; Unchanged drug;		DRUGBANK
Eliminate Route	6.5	%	6.5±4.3	%	Urinary excretion; Unchanged drug;		The Pharmacological Basis of Therapeutics
Protein Binding	20.0	%	20	%		dose → ;	DRUGBANK
Protein Binding	13.0	%	13	%			The Pharmacological Basis of Therapeutics

Property Name	Property Value	Unit	Raw Value	Raw Unit	Annotation	Brand Name	Component	Reference
Max dose for children	50.0	mg/kg	50	mg/kg	intravenous injection, IV	Cyclophosphamide Tablets	cyclophosphamide	PDR
Max dose for children	5.0	mg/kg/day	5	mg/kg/day	PO, oral	Cyclophosphamide Tablets	cyclophosphamide	PDR
Max dose for adolescents	60.0	mg/kg/day	60	mg/kg/day	intravenous injection, IV	Cyclophosphamide Tablets	cyclophosphamide	PDR
Max dose for adolescents	15.0	mg/kg/day	15	mg/kg/day	intravenous injection, IV	Cyclophosphamide Tablets	cyclophosphamide	PDR
Max dose for adolescents	2300.0	mg/m2/day	2.3	g/m2/day	intravenous injection, IV	Cyclophosphamide Tablets	cyclophosphamide	PDR
Max dose for adolescents	80.0	mg/kg/day	80	mg/kg/day	intravenous injection, IV	Cyclophosphamide Tablets	cyclophosphamide	PDR
Max dose for adolescents	50.0	mg/m2/day	50	mg/m2/day	PO, oral	Cyclophosphamide Tablets	cyclophosphamide	PDR
Max dose for elderly	60.0	mg/kg/day	60	mg/kg/day	intravenous injection, IV	Cyclophosphamide Tablets	cyclophosphamide	PDR
Max dose for elderly	15.0	mg/kg/day	15	mg/kg/day	intravenous injection, IV	Cyclophosphamide Tablets	cyclophosphamide	PDR
Max dose for elderly	2.3	g/m2/day	2.3	g/m2/day	intravenous injection, IV	Cyclophosphamide Tablets	cyclophosphamide	PDR
Max dose for elderly	80.0	mg/kg/day	80	mg/kg/day	intravenous injection, IV	Cyclophosphamide Tablets	cyclophosphamide	PDR
Max dose for elderly	50.0	mg/m2/day	50	mg/m2/day	PO, oral	Cyclophosphamide Tablets	cyclophosphamide	PDR

Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1